News from viiv healthcare A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 12, 2013, 18:22 ET

ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1

 ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. This open-label study, for the first time,...

Sep 04, 2013, 09:00 ET

ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern U.S.

 ViiV Healthcare announced today the first Positive Action Southern Initiative (PASI) grant awardees in Texas and Virginia and seven grant...

Aug 14, 2013, 19:16 ET

ViiV Healthcare anuncia la aprobación de Tivicay® (dolutegravir) en EE. UU. para el tratamiento del VIH-1

ViiV Healthcare tiene el gusto de anunciar hoy que la Administración de Drogas y Alimentos (Food and Drug Administration, FDA) de los...

Aug 12, 2013, 22:54 ET

UPDATE: Multimedia Assets Now Available: ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1

ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay® (dolutegravir) 50-mg...

Aug 12, 2013, 20:48 ET

ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1

ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay® (dolutegravir) 50-mg...

Nov 08, 2012, 03:30 ET

ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children

ViiV Healthcare announced today that it has awarded nearly £4 million to 99 projects in 26 countries through its Positive Action for Children...

Jul 26, 2012, 16:30 ET

Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced 48-week data from the SPRING-2 Phase III study, which is evaluating the investigational integrase...

Jul 18, 2012, 04:00 ET

ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

ViiV Healthcare today announced a broad range of groundbreaking initiatives as part of its ongoing commitment to address the gaps in care and...

Jul 11, 2012, 02:08 ET

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the...

Apr 02, 2012, 02:09 ET

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV

 ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III...

Oct 13, 2011, 09:00 ET

ViiV Healthcare's Positive Action for Children Fund Announces 16 New Grantees for the Year 2011/2012

ViiV Healthcare announced today that it has awarded approximately 3.9 million pounds Sterling to 16 organisations in eight countries, through its...

Oct 12, 2011, 19:07 ET

'ViiV Healthcare Effect' haucht den positiven Aktionspartnerschaften von ViiV Healthcare Leben ein

- Persönliche Geschichten, Lebenserfahrungen und Kooperationen auf neuer Website vorgestellt WAS: Der ViiV Healthcare Effect...

Oct 12, 2011, 18:55 ET

'ViiV Healthcare Effect' proporciona asociaciones de acción positivas para la vida de ViiV Healthcare

- La nueva página web muestra las historias personales, experiencias de la vida real y colaboraciones QUÉ: ViiV Healthcare...

Oct 12, 2011, 13:58 ET

"ViiV Healthcare Effect"dá vida a parcerias da Ação Positiva da ViiV Healthcare

O QUE: O ViiV Healthcare Effect (www.ViiVHealthcareEffect.com) apresenta a abordagem de nossa empresa a parcerias, de uma forma única e...

Oct 12, 2011, 13:47 ET

'ViiV Healthcare Effect' donne vie aux partenariats Action positive de ViiV Healthcare

  - Un nouveau site Web présente des histoires personnelles, des expériences dans la vraie vie et des collaborations SUJET :...

Oct 12, 2011, 05:00 ET

'ViiV Healthcare Effect' hace realidad las asociaciones para la acción positiva de ViiV Healthcare

QUÉ: ViiV Healthcare Effect (www.ViiVHealthcareEffect.com) presenta el enfoque de nuestra compañía a las asociaciones de un...

Oct 12, 2011, 05:00 ET

'ViiV Healthcare Effect' Brings ViiV Healthcare's Positive Action Partnerships to Life

WHAT: The ViiV Healthcare Effect (www.ViiVHealthcareEffect.com) introduces our company's approach to partnerships in a unique and personal way....

Oct 11, 2011, 09:00 ET

ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV

ViiV Healthcare announces the start of the Phase III MODERN Study [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen],...

Feb 03, 2011, 03:00 ET

Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new...

Oct 21, 2010, 04:00 ET

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

Shionogi-ViiV Healthcare LLC today announced the start of the Phase III clinical programme evaluating its once-daily, unboosted investigational...